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Hazardous alcohol consumption among women with human immunodeficiency virus (HIV) infection is associ-
ated with several adverse health and behavioral outcomes, but the proportion of HIV-positive women who engage
in hazardous drinking over time is unclear. The authors sought to determine rates of hazardous alcohol consump-
tion among these women over time and to identify factors associated with this behavior. Subjects were 2,770 HIV-
positive women recruited from 6 US cities who participated in semiannual follow-up visits in the Women’s
Interagency HIV Study from 1995 to 2006. Hazardous alcohol consumption was defined as exceeding daily
(4 drinks) or weekly (>7 drinks) consumption recommendations. Over the 11-year follow-up period, 14%–24%
of the women reported past-year hazardous drinking, with a slight decrease in hazardous drinking over time.
Women were significantly more likely to report hazardous drinking if they were unemployed, were not high school
graduates, had been enrolled in the original cohort (1994–1995), had a CD4 cell count of 200–500 cells/mL, were
hepatitis C-seropositive, or had symptoms of depression. Approximately 1 in 5 of the women met criteria for
hazardous drinking. Interventions to identify and address hazardous drinking among HIV-positive women are
urgently needed.
alcohol drinking; HIV; longitudinal studies; women
Abbreviations: HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; HIV, human immunodeficiency virus; WIHS,
Women’s Interagency HIV Study.
Between 1990 and 2000, the US human immunodefi-
ciency virus (HIV) epidemic expanded to increasingly
include women. Today, women account for more than
one-quarter of all new diagnoses of HIV infection and ac-
quired immunodeficiency syndrome in the United States (1).
As a growing number of women become infected with HIV,
the need to identify and address modifiable factors that af-
fect disease progression or survival becomes more urgent.
Hazardous alcohol use is one such modifiable behavior.
Hazardous alcohol use is defined as a pattern of alcohol
consumption that is associated with an increase in alcohol-
related or other health problems but may not necessarily be
classified as alcoholism (2). The National Institute on Alco-
hol Abuse and Alcoholism defines hazardous alcohol use for
women as an average consumption of>7 drinks per week or
4 drinks at 1 sitting at least weekly. It is important to
distinguish hazardous alcohol use from nonhazardous use,
since low-to-moderate levels of alcohol consumption are
often associated with improved health outcomes and sur-
vival, whereas hazardous consumption is associated with
poorer outcomes (3, 4).
Although studies carried out before the era of highly ac-
tive antiretroviral therapy (HAART) did not find alcohol
consumption to be associated with disease progression (5),
more recent studies have demonstrated a significant associ-
ation between hazardous alcohol consumption and several
adverse health outcomes and behaviors in HIV-positive
women. These include increased HIV viral load, lower
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medication adherence, increased risky sexual behavior, and
more rapid disease progression (6–12). Women who are
coinfected with HIVand hepatitis C virus (HCV) are at even
greater risk of alcohol-associated health problems.
Previous studies have suggested that 6%–54% of HIV-
positive women meet criteria for hazardous drinking in dif-
ferent settings, depending on the specific measure of haz-
ardous drinking used (6, 13–16). These studies were limited
by assessment at only 1 time point or recruitment from
a single setting. Longitudinal assessment of alcohol con-
sumption is important, because drinking behavior may
change with increasing age or with HIV disease progression.
Drinking patterns may also be influenced by period effects
(factors common to all age groups at a particular time point)
or cohort effects (factors common to all women enrolled in
a study in a given year) (17). Furthermore, many drinkers do
not show consistent behavior, varying their drinking pattern
and volume over time (17).
Here we describe longitudinal patterns of alcohol con-
sumption in HIV-positive women. Identification of demo-
graphic, clinical, or behavioral characteristics of women at
increased risk for hazardous drinking might help clinicians
recognize those women, so that increased screening, pre-
vention, and therapeutic services could be provided. Our
objectives in this study were to determine the proportion
of HIV-positive women with hazardous alcohol consump-
tion over 11 years of follow-up and to identify factors asso-
ciated with hazardous drinking in these women.
MATERIALS AND METHODS
Study population
Data were obtained from women participating in the
Women’s Interagency HIV Study (WIHS), the largest ongo-
ing longitudinal cohort study of HIV-positive women in the
United States. The WIHS is a multicenter, prospective study
that was established in 1994 to carry out comprehensive
investigations of the impact of HIV infection among women
aged 18 years. In a second recruitment phase, new mem-
bers were enrolled in the study during 2000–2001. Women
are seen at semiannual study visits. Our analyses were lim-
ited to 2,770 women who were confirmed by serologic
analysis to be HIV-positive at study entry.
Participating study sites are centered in the Bronx and
Brooklyn, New York; Washington, DC; Los Angeles and
San Francisco, California; and Chicago, Illinois. WIHS par-
ticipants were recruited from a variety of sources, including
HIV primary care clinics, hospital-based programs, research
programs, community outreach sites, women’s support
groups, drug rehabilitation programs, HIV testing sites,
and referrals from enrolled participants. The study design
has been described previously (18, 19), and additional infor-
mation is available at the study’s Web site (https://statepiaps.
jhsph.edu/wihs/).
The WIHS participants undergo semiannual physical ex-
aminations, complete study questionnaires, and provide
blood for biomarker measurements. The semiannual ques-
tionnaire data are obtained face to face by interviewers who
receive extensive standardized training regarding how to ask
questions on sensitive issues and how to minimize social
desirability bias. Participants who report heavy alcohol con-
sumption or drug use during the interviews are referred to
substance abuse treatment programs in the community with
established linkages to the WIHS sites. The number of
women who pursue such referrals is not known.
Institutional review boards at each of the study centers
and their community affiliates approved the WIHS proto-
cols, and informed written consent was obtained from all
participants.
Measures
Alcohol consumption. The WIHS has collected data on
quantity and frequency of alcohol consumption since its
inception. At each visit, WIHS participants are asked to
report the average number of days per week on which they
have consumed an alcoholic drink since their previous as-
sessment 6 months earlier. A drink is defined as ‘‘1 can,
bottle, or glass of beer, a glass of wine, a shot of liquor,
a mixed drink with that amount of liquor, or any other kind
of alcoholic beverage.’’ Response options are every day, 5–6
days per week, 3–4 days per week, 1–2 days per week, less
than once per week, and none. Next, participants are asked
about the usual number of drinks they have consumed per
day since their previous assessment. Open-ended responses
were elicited between 1996 and 2002, and choices were
categorized for visits taking place after October 2002
(0, 1–2, 3–4, 5–6, or7 drinks per day).Open-ended responses
such as ‘‘a pint of vodka’’ (0.5 L) are converted to numbers
of standard drinks. At baseline, women also provided in-
formation on whether they had ever received treatment for
problematic alcohol consumption, and if so, which type of
treatment (e.g., inpatient alcohol detoxification, outpatient al-
cohol detoxification, attendance at Alcoholics Anonymous).
Using the WIHS data from visits 1–23 (1995–2006), we
created 2 types of alcohol consumption measures based on
the 2 questions relating to hazardous drinking and based the
cutpoint for these analyses on guidelines issued by the
National Institute onAlcoholAbuse andAlcoholism (2). First,
we calculated the average quantity of drinks per week by
multiplying quantity by frequency. For response items that
involved a range, we used the midpoint of the range. Weekly
consumption was also categorized as >7 drinks per week
(excessive weekly consumption) or 7 drinks per week.
Second, we used the average number of drinks consumed
per day to categorize women into those who consumed 4
drinks per day (excessive daily consumption) and those who
consumed <4 drinks per day. Then, using these cutpoints at
each visit, we categorized a woman’s alcohol consumption
into 1 of 3 groups: hazardous drinking (>7 drinks per week
or 4 drinks per day), moderate drinking (any drinking that
did not qualify as hazardous drinking), or nondrinking. We
also created a dichotomous variable for any hazardous
drinking in the past year (i.e., current visit or previous visit).
Additional measures. Women provided information
about their age, race, educational attainment, marital status,
and employment status at the time of study enrollment. We
categorized the women according to their geographic site of
enrollment and study enrollment time (original cohort,
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recruited in 1994–1995, or second cohort, recruited in
2001–2002). Illicit drug use was assessed at each visit by
asking participants to indicate the quantity and frequency of
use of the following substances since their previous visit:
tobacco, marijuana, cocaine, ‘‘crack’’ or freebase cocaine,
heroin, and methadone. Current drug use was defined as
taking the drug at least once per month. Participants also
reported whether they had ever injected any drugs and
whether they were currently injecting drugs.
At each visit, a CD4 cell count was determined, with the
results categorized as <200 cells/mL, 200–500 cells/mL,
and >500 cells/mL. Hepatitis C infection was determined
by antibody testing from blood collected at study enrollment
(actual testing was done several years after enrollment).
Symptoms of depression were measured at each visit with
the 20-item Center for Epidemiologic Studies Depression
Scale (20); women were classified as having symptoms of
depression if they had a score of 16.
Statistical analyses
We compared characteristics of HIV-positive women with
and without hazardous drinking behavior at baseline or the
first follow-up visit. We used the t test to compare mean
values and the chi-squared test to compare categorical var-
iables (SAS, version 9.1; SAS Institute Inc., Cary, North
Carolina). Next, we used multivariable logistic regression
to assess the effect of sociodemographic and clinical vari-
ables on the risk of hazardous drinking at each visit. We
used a generalized estimating equations approach, allowing
participants to contribute data from each time point, with
adjustment for repeated measures within subjects. All socio-
demographic factors and clinical variables were selected for
the initial model, with the exception of drug use, which was
left out of the model because of significant collinearity with
the alcohol measure. Using stepwise elimination, the least
significant variable was dropped from the current model
until all of the variables left in the model were significant
(P < 0.05). The corresponding estimates were compared
with the initial estimates from the full model, and the
changes were negligible. These analyses were repeated in
a stratified manner according to WIHS enrollment cohort
date (1995–1996 or 2001–2002); since the results were sim-
ilar, we present the combined data as representative of the
entire sample.
We plotted the proportion of women with hazardous
drinking or moderate drinking in the past year, overall and
stratified by HCV status at baseline. To assess whether the
proportion of women who were hazardous drinkers might be
affected by study loss to follow-up or differential survival
rates, we repeated these analyses using only data from
women who completed 1 of the last 2 visits. The observed
trends were similar; therefore, we present results from the
entire cohort.
RESULTS
Baseline characteristics of the 2,770 HIV-infected
women, overall and stratified by baseline hazardous drink-
ing behavior pattern, are shown in Table 1. Women report-
ing hazardous drinking at baseline were significantly more
likely to be older than 40 years, to be African-American, to
be unemployed, to have not completed high school, or to be
part of the original (1994–1995) cohort. Women with haz-
ardous drinking patterns were also significantly more likely
to be HCV-seropositive and to have high levels of depressive
symptoms. They were also more likely to smoke cigarettes,
to use other drugs, and to report current or past injection
drug use.
Among women who did not engage in hazardous drinking
at baseline, 981 (45%) were drinking at moderate levels, 380
(17%) were current nondrinkers with a history of hazardous
drinking, and 825 (37%) were current nondrinkers with no
history of hazardous drinking. Among women who did en-
gage in hazardous drinking at baseline, 138 (25%) exceeded
weekly consumption levels only, 142 (25%) exceeded daily
consumption levels only, and 282 (50%) exceeded both
weekly and daily consumption levels. Overall, 17% of the
women had received 1 or more types of treatment for alco-
hol problems in the past, with the most common being
inpatient alcohol detoxification (13%), Alcoholics Anony-
mous attendance (12%), and outpatient alcohol detoxifica-
tion (8%).
Figure 1 shows the proportion of women who had con-
sumed alcohol in the previous year during the period 1995–
2006. Over this interval, 14%–24% of women met the
criteria for hazardous drinking, and 32%–48% of women
met the criteria for moderate drinking. There was a gradual
decline in the proportion of women who met the criteria for
hazardous drinking over time, with a corresponding increase
in the proportion of women who met the criteria for mod-
erate drinking during follow-up.
Figure 2 shows the proportion of HIV-positive women
who reported hazardous drinking in the previous year ac-
cording to their HCV serostatus at study enrollment. In the
mid-to-late 1990s, HCV-seropositive women were much
more likely to be hazardous drinkers than HCV-seronegative
women. However, this difference decreased over time, and
there was no significant difference in hazardous drinking
behavior according to HCV status at the most recent time
points.
In multivariable analysis, women were slightly but statis-
tically significantly less likely to engage in hazardous drink-
ing with each follow-up visit, a finding that was independent
of age (Table 2). Women were also significantly less likely
to be hazardous drinkers if they were employed at baseline
or if they had completed high school. In contrast, women
were significantly more likely to be hazardous drinkers if
they had CD4 cell counts of 200–500 cells/mL, were HCV-
seropositive, or had high levels of depressive symptoms.
There was no significant association of hazardous drinking
with age, race, or enrollment cohort.
DISCUSSION
In this paper, we report patterns of alcohol consumption
between 1995 and 2006 over time in a geographically di-
verse sample of 2,770 HIV-positive women from the WIHS
cohort. We found that at any time point, 14%–24% of
Alcohol Consumption in HIV-Positive Women 1027
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Table 1. Baseline Characteristics of HIV-Positive Women According to Self-reported Alcohol Consumption Status During the Past Year,
Women’s Interagency HIV Study, 1995–2006









No. % No. % No. %
Sociodemographic factors
Mean age,b years 36 (7.8)c 37 (7.3) 36 (7.9) 0.06
Age group,b years
<30 642 23.2 102 18.2 540 24.5
30–40 1,334 48.2 257 45.7 1,077 48.8
>40 791 28.6 203 36.1 588 26.7 <0.0001
Race
White (non-Hispanic) 422 15.2 79 14.1 343 15.5
African-American (non-Hispanic) 1,606 58.0 366 65.1 1,240 56.2
Hispanic 654 23.6 104 18.5 550 24.9
Other 88 3.2 13 2.3 75 3.4 0.001
Marital statusb
Single (never married) 910 33.4 200 36.0 710 32.7
Married 1,010 37.0 192 34.6 818 37.7
Separated/divorced/widowed 807 29.6 163 29.4 644 29.7 0.27
Employedb 671 24.3 84 15.0 587 26.6 <0.0001
More than a high school educationb 878 31.8 141 25.1 737 33.5 0.0002
Study site
Bronx, New York 545 19.7 103 18.3 442 20.0
Brooklyn, New York 454 16.4 77 13.7 377 17.1
Washington, DC 411 14.8 79 14.1 332 15.0
Los Angeles, California 569 20.5 99 17.6 470 21.3
San Francisco, California 419 15.1 109 19.4 310 14.0
Chicago, Illinois 372 13.4 95 16.9 277 12.5 0.0006
Enrollment cohort
1994–1995 2,041 73.7 493 87.7 1,548 70.1
2001–2002 729 26.3 69 12.3 660 29.9 <0.0001
Clinical characteristics
CD4 cell count,b cells/mL
<200 660 24.6 119 22.0 541 25.2
200–500 1,164 43.4 254 47.0 910 42.4
>500 860 32.0 167 30.9 693 32.3 0.13
Hepatitis C-seropositiveb 948 35.3 290 53.0 658 30.7 <0.0001
Depressive symptoms (CES-D score 16)b 1,467 54.1 366 66.7 1,101 50.9 <0.0001
Drug useb
Current use
Cocaine 321 11.6 170 30.2 151 6.8 <0.0001
Heroin 282 10.2 121 21.5 161 7.3 <0.0001
Crack/freebase cocaine 437 15.8 222 39.5 215 9.7 <0.0001
(Illicit) methadone 38 1.4 19 3.4 19 0.9 <0.0001
Marijuana/hashish 591 21.4 236 42.1 355 16.1 <0.0001
Tobacco 1,415 51.1 437 77.8 978 44.4 <0.0001
Ever use of injected drugs 914 33.0 292 52.0 622 28.2 <0.0001
Abbreviations: CES-D, Center for Epidemiologic Studies Depression [Scale]; HIV, human immunodeficiency virus.
a Hazardous drinking was defined as excessive weekly consumption (>7 drinks per week) or excessive daily consumption (4 drinks per
occasion). Information on drinking status for the first 2 visits was missing for 45 women.
b Information on this measure was missing for some women.
c Numbers in parentheses, standard deviation.
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women reported consumption of alcohol at hazardous levels
in the past year, while over 50% of women had consumed
any alcohol.
The proportion of women with hazardous drinking at any
time point in our study was similar to or greater than the
proportion in other cross-sectional studies that evaluated
hazardous alcohol consumption among HIV-positive
women (6%–54%) (6–12). However, it is difficult to directly
compare proportions of women with hazardous drinking
across these studies because of differences in the measure-
ment of hazardous drinking. The proportions in our sample
were also similar to a recent (2001–2002) general popula-
tion estimate for US women aged 18 years or older, which
found that 22% of US adult women engage in hazardous
drinking (21).
Our analysis differs from previous studies of hazardous
drinking in HIV-positive women by documenting trends
over time. This allowed us to see, for example, that the
proportion of women with hazardous drinking behavior de-
clined gradually during the time period of 1995–2006,
whereas the overall proportion of women with any alcohol
consumption remained stable. Several other studies have
demonstrated a gradual decrease in hazardous drinking with
increasing age (17, 22). However, there is also evidence of
Figure 1. Proportions of 2,770 human immunodeficiency virus (HIV)-positive women reporting having engaged in hazardous drinking and
nonhazardous drinking during the past year, Women’s Interagency HIV Study, 1995–2006. The alcohol measurement items were modified slightly
in 2002.
Figure 2. Proportion of 2,770 human immunodeficiency virus (HIV)-positive women reporting having engaged in hazardous drinking during the
past year, according to their hepatitis C virus status at baseline, Women’s Interagency HIV Study, 1995–2006.
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mixed longitudinal patterns, with a significant proportion of
older women initiating hazardous drinking in middle to late
life (22). Our finding that the decrease in hazardous drinking
over time was independent of age or study cohort suggests
that the trend may represent a period effect, which refers to
general changes in the population related to year of data
collection (23). We also considered whether the gradual de-
crease in hazardous drinking could be related to differential
loss to follow-up or shorter survival among women with
hazardous drinking, but additional analyses did not support
this explanation. Although researchers in prior analyses of
retention rates among women enrolled in the original cohort
did not find a difference between heavier drinkers and those
who drank less (24), further investigation of the relation
between hazardous drinking and survival is warranted.
To date, conclusions about the relative impact of hazard-
ous drinking on major health outcomes such as survival or
disease progression in HIV-positive persons have been
mixed. In the pre-HAART era, most studies showed no ev-
idence of an effect of alcohol consumption on survival (5,
25). However, in more recent studies, investigators have
concluded that hazardous alcohol consumption is correlated
with more rapid disease progression (9, 10, 12). One possi-
ble hypothesis regarding this shift is that in the HAART era,
people with HIV infection are feeling better and therefore
continuing or increasing their use of recreational substances
such as alcohol. Alternatively, hazardous drinking could di-
rectly shorten survival through its effects on the immune
system, adverse health behaviors such as nonadherence to
medication protocols, or HIV-related comorbid conditions
such as hepatitis.
The fact that women with HCV infection drank as much
as or more than women without HCV is concerning, al-
though the steeper decline in rates of hazardous drinking
among women infected with both HIV and HCV is reassur-
ing. Liver disease, mostly related to HCV, is now the leading
cause of non-HIV-related death in women with HIV/
acquired immunodeficiency syndrome (26). Hazardous al-
cohol consumption is also a significant barrier to receiving
treatment for HCV infection (27). The more rapid decline
among women dually infected with both HIV and HCV
could be due to increased awareness and clinical interven-
tion, to decreased survival, or to some combination of these
factors. In this study, baseline HCVantibody testing was not
conducted for several years. Therefore, many women were
not initially aware of their HCV status, and they may have
reduced their drinking only after learning they were HCV-
seropositive (28).
The overlap of hazardous alcohol consumption with drug
use is also important to note. At baseline, over one-third of
the women with hazardous drinking also had a history of
injection or noninjection drug use. The relative contribution
of hazardous alcohol consumption versus other drugs to ma-
jor health outcomes in HIV infection can be difficult to dis-
cern. Noninjection drug use has been associated with HIV
progression and all-cause mortality in this cohort (29). In
addition, nearly all of the women with HCV infection in this
sample had a history of current or past injection drug use,
which could party explain the increased prevalence of haz-
ardous drinking among HCV-seropositive women.
Several issues related to self-reported alcohol consump-
tion measures warrant mention. Only a few alcohol con-
sumption measurements were obtained at each semiannual
study visit (i.e., quantity and frequency), limiting our ability
to examine participants for additional drinking patterns such
as periodic binge drinking. Measures of quantity and fre-
quency also occasionally lead to underestimates in compar-
ison with other drinking assessment methods (30). In
addition, the definition of a standard drink of alcohol may
have been inconsistent across women. Early in the study,
women could indicate specific types of beverages and
amounts that did not easily translate into numbers of stan-
dard drinks (e.g., a pint (0.5 L) of vodka). However, later in
the study, we did not obtain this open-ended information,
which could account for part of the observed shift from
hazardous drinking to moderate drinking during the last
few years of follow-up. Hazardous drinking was estimated
for some women because of response items that included
ranges, and because drinking patterns during the past month
could have varied. Social desirability can also result in un-
derestimation of heavy drinking in some women. Although
these measurement biases could point in either direction,
Table 2. Significant Predictors of Hazardous Alcohol Consumptiona
at Each Time Point in HIV-Positive Women (Multivariate Analyses),







Current visit (vs. previous visit) 0.96 0.96, 0.97 <0.0001
Employment (yes vs. no) 0.80 0.72, 0.90 0.0002
More than a high school
education (vs. high school
or less)
0.72 0.59, 0.87 0.0009
Study site
Brooklyn, New York 1 Referent
Bronx, New York 1.15 0.87, 1.52 0.33
Washington, DC 1.65 1.23, 2.21 0.0009
Los Angeles, California 1.18 0.87, 1.59 0.28
San Francisco, California 1.49 1.12, 1.99 0.007
Chicago, Illinois 1.31 0.96, 1.77 0.09
CD4 cell count, cells/mL
>500 1 Referent
200–500 1.10 1.00, 1.21 0.05
<200 1.06 0.95, 1.24 0.22
Hepatitis C-seropositive
(yes vs. no)




1.31 1.21, 1.43 <0.0001
Abbreviations: CES-D, Center for Epidemiologic Studies Depres-
sion [Scale]; HIV, human immunodeficiency virus.
a Hazardous drinking was defined as excessive weekly consump-
tion (>7 drinks per week) or excessive daily consumption (4 drinks
per occasion).
b Other variables in the model that were not statistically significant
included age, race, and enrollment cohort (1994–1995 or 2001–
2002).
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they are probably more likely to underestimate drinking,
and thus the true rate of hazardous drinking could be higher.
In summary, 14%–24% of HIV-positive women in the
WIHS met criteria for past-year hazardous drinking over
a decade of follow-up. Although more than half of the
HIV-positive women in this study consumed at least some
alcohol, interventions should attempt to target those women
who are drinking at hazardous or unhealthy levels. In the
current era of HAART, hazardous drinking could have
a greater impact on health outcomes because of its associ-
ation with nonadherence to medication protocols. Data col-
lection for the WIHS started at the beginning of the HAART
era, and it is possible that some women cut down on their
drinking in order to improve their chances of survival.
Women with additional risk factors such as depression or
HCV coinfection may need even more intensive screening
and targeted intervention. Advice on how to screen and in-
tervene is available (2, 31, 32); yet despite the consistent
evidence of harm associated with hazardous drinking, in
many clinical settings hazardous alcohol consumption is
often neither detected nor addressed (33). Although the
study design does not allow for formal cause-effect conclu-
sions, these findings suggest that women with identified risk
factors such as depression or HCV infection may need ad-
ditional or more aggressive screening for hazardous drink-
ing. Further research and guidance are needed to translate
effective alcohol-related interventions into clinical practice
and to determine the impact of such interventions on the
health outcomes of women with HIV infection.
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